AstraZeneca Pharma India Limited has informed the Exchange that Board of Directors at its meeting held on May 30, 2025, recommended Final Dividend of 32 per equity share.
ASTRAZEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 15.9 pts more than Nifty Microcap 250 and 16.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board of Directors of AstraZeneca Pharma India Limited, at its meeting held on May 30, 2025, has recommended a Final Dividend of ₹32 per equity share for shareholders. This is a recommendation by the Board and would require shareholder approval at the upcoming Annual General Meeting. The dividend amount is on a per-share basis; the total payout will depend on the number of outstanding shares. No record date or payment timeline has been mentioned in this announcement.
A positive signal for income-seeking shareholders, as it indicates the company is returning cash to investors. However, without prior dividend figures or the current share price, it is difficult to gauge whether this represents an increase, decrease, or a meaningful yield.